Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma

医学 彭布罗利珠单抗 内科学 肿瘤科 头颈部鳞状细胞癌 危险系数 放射治疗 阶段(地层学) 头颈部癌 外科 癌症 置信区间 免疫疗法 生物 古生物学
作者
Trisha M. Wise‐Draper,Shuchi Gulati,Sarah Palackdharry,Benjamin H. Hinrichs,Francis P. Worden,Matthew Old,Neal E. Dunlap,John M. Kaczmar,Yash Patil,Muhammed Kashif Riaz,Alice Tang,Jonathan Mark,Chad Zender,Ann M. Gillenwater,Diana Bell,Nicky Kurtzweil,Maria Mathews,Casey L. Allen,Michelle Mierzwa,Keith Casper,Roman Jandarov,Mario Medvedovic,John Lee,Nusrat Harun,Vinita Takiar,Maura L. Gillison
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (7): 1345-1352 被引量:41
标识
DOI:10.1158/1078-0432.ccr-21-3351
摘要

Abstract Purpose: Patients with resected, local–regionally advanced, head and neck squamous cell carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune-checkpoint blockade (ICB) has demonstrated clinical activity, but biomarkers of response and effect on survival remain unclear. Patients and Methods: Eligible patients had resectable squamous cell carcinoma of the oral cavity, larynx, hypopharynx, or oropharynx (p16-negative) and clinical stage T3-T4 and/or two or more nodal metastases or clinical extracapsular nodal extension (ENE). Patients received neoadjuvant pembrolizumab 200 mg 1–3 weeks prior to surgery, were stratified by absence (intermediate-risk) or presence (high-risk) of positive margins and/or ENE, and received adjuvant radiotherapy (60–66 Gy) and concurrent pembrolizumab (every 3 weeks × 6 doses). Patients with high-risk HNSCC also received weekly, concurrent cisplatin (40 mg/m2). Primary outcome was one-year DFS. Secondary endpoints were one-year overall survival (OS) and pathologic response (PR). Safety was evaluated with CTCAE v5.0. Results: From February 2016 to October 2020, 92 patients enrolled. The median age was 59 years (range, 27–80), 30% were female, 86% had stage T3–T4, and 69% had ≥N2. At a median follow-up of 28 months, one-year DFS was 97% (95% CI, 71%–90%) in the intermediate-risk group and 66% (95% CI, 55%–84%) in the high-risk group. Patients with a PR had significantly improved one-year DFS relative to patients without response (93% vs. 72%, hazard ratio 0.29; 95% CI, 11%–77%). No new safety signals were identified. Conclusions: Neoadjuvant and adjuvant pembrolizumab increased one-year DFS rate in intermediate-risk, but not high-risk, HNSCC relative to historical control. PR to neoadjuvant ICB is a promising surrogate for DFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
斯文败类应助CC悟了采纳,获得10
1秒前
panjunlu完成签到,获得积分10
2秒前
澡雪发布了新的文献求助10
3秒前
tcf发布了新的文献求助10
5秒前
吴祥坤发布了新的文献求助10
6秒前
11秒前
11秒前
练习时长两年半应助飞鱼采纳,获得20
11秒前
Honor完成签到 ,获得积分10
11秒前
吴祥坤完成签到,获得积分10
14秒前
yxl完成签到,获得积分10
14秒前
俭朴咖啡完成签到 ,获得积分10
15秒前
16秒前
紫罗风韵完成签到,获得积分10
16秒前
CC完成签到,获得积分10
16秒前
17秒前
三石呦423发布了新的文献求助10
18秒前
18秒前
阿州关注了科研通微信公众号
19秒前
昱珂发布了新的文献求助10
19秒前
17完成签到,获得积分10
19秒前
紫薇的舔狗完成签到,获得积分10
21秒前
22秒前
吱吱发布了新的文献求助10
22秒前
23秒前
小马甲应助科研欣路采纳,获得10
24秒前
翁雁丝发布了新的文献求助10
24秒前
26秒前
26秒前
佳子发布了新的文献求助10
27秒前
缓慢咖啡完成签到,获得积分10
28秒前
热心念瑶发布了新的文献求助30
28秒前
可爱的函函应助安好采纳,获得10
29秒前
29秒前
30秒前
30秒前
30秒前
佳子完成签到,获得积分20
32秒前
SYLH应助友好的寒云采纳,获得20
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975661
求助须知:如何正确求助?哪些是违规求助? 3520000
关于积分的说明 11200535
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390